10-Q: OptiNose Reports Q1 2025 Results, Highlights XHANCE Growth Amidst Merger Agreement with Paratek

OptiNose, Inc. announces its first quarter 2025 financial results, showcasing increased XHANCE prescriptions and revenue per prescription, while also addressing liquidity concerns and an impending merger with Paratek Pharmaceuticals.

Summary

• OptiNose, Inc. reported a net loss of $22.4 million for the first quarter of 2025, compared to a net loss of $14.1 million for the same period in 2024.
• Net product revenues for XHANCE increased to $18.5 million in Q1 2025 from $14.9 million in Q1 2024.
• The company's average net product revenue per prescription was $260 in Q1 2025, a 14% increase from $227 in Q1 2024.
• Total XHANCE prescriptions rose by 9% to 71,300 in Q1 2025.
• The company is facing liquidity challenges and has substantial doubt about its ability to continue as a going concern.
• OptiNose entered into a merger agreement with Paratek Pharmaceuticals, expected to close around May 21, 2025, pending stockholder approval.
• The merger consideration includes $9.00 in cash and one contingent value right (CVR) per share.
• The CVRs offer potential payments of $1.00 and $4.00 based on achieving certain net sales milestones for XHANCE.
• The company believes its existing cash and cash equivalents will be sufficient to fund operations and debt service obligations into the first quarter of 2026, assuming compliance with debt covenants.
• OptiNose is required to conduct clinical trials of XHANCE in adolescent patients as part of FDA approvals.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss and going concern uncertainty, despite positive trends in XHANCE prescriptions and revenue per prescription; the merger agreement provides some optimism, but the company's financial challenges weigh heavily.

Positives

• XHANCE prescriptions increased by 9% year-over-year, indicating growing market acceptance.
• Average net revenue per prescription increased by 14%, improving profitability.
• The merger agreement with Paratek Pharmaceuticals provides shareholders with an upfront cash payment and potential future value through CVRs.
• The company has launched a central in-take pharmacy model (HUB) to improve patient support and prescription fulfillment services.
• XHANCE has received FDA approval for the treatment of chronic rhinosinusitis without nasal polyps, expanding its market opportunity.

Negatives

• The company reported a net loss of $22.4 million for Q1 2025, an increase from the $14.1 million loss in Q1 2024.
• OptiNose faces substantial doubt about its ability to continue as a going concern.
• The company may not be able to maintain compliance with debt covenants under the A&R Note Purchase Agreement.
• The company is dependent on maintaining compliance with debt covenants or obtaining waivers or modifications.
• The company will need to begin making principal repayments on its debt in eight quarterly installments of $16.3 million each through maturity in June 2027.

Risks

• Failure to maintain compliance with financial covenants under the A&R Note Purchase Agreement could lead to an event of default.
• The company's ability to continue as a going concern is dependent on achieving certain minimum XHANCE net sales and royalties.
• The company may need to delay or curtail operations if additional funding is not obtained.
• The merger with Paratek is subject to stockholder approval and other closing conditions.
• Payor utilization management criteria could negatively impact XHANCE prescription volumes.
• The company is subject to legal proceedings related to the merger agreement.

Future Outlook

The company anticipates the merger with Paratek will be consummated around May 21, 2025, pending stockholder approval and satisfaction of other closing conditions; the company believes its existing cash and cash equivalents would be sufficient to fund its operations and debt service obligations into the first quarter of 2026, assuming compliance with debt covenants.

Management Comments

• The company is relaunching XHANCE to focus on the comparatively larger market opportunity that we believe is created by the new indication.
• The company plans to continue to focus our commercial efforts primarily to the ENT and allergy specialist audience while seeking partnerships to extend the commercialization of XHANCE into primary care.
• Successfully growing XHANCE prescribing in this audience, as well as our existing prescribing base, will be important to achieving our near and long term financial objectives.
• The company believes it is beginning to realize the benefits of the Hub model as we continue to optimize processes at the Hub and physician offices become familiar with working with the Hub.

Industry Context

The chronic rhinosinusitis market is a significant area of unmet need, with existing treatments like intranasal steroids having limitations; XHANCE aims to address these limitations with its proprietary Exhalation Delivery System, potentially becoming a standard of care.

Comparison to Industry Standards

• It is difficult to compare OptiNose directly to industry standards without specific competitor data for XHANCE.
• However, companies like Glenmark Pharmaceuticals and Teva Pharmaceuticals are major players in the nasal spray market.
• These companies have generic and branded products for allergic rhinitis and sinusitis.
• OptiNose's XHANCE differentiates itself through its unique delivery system, but faces competition from established products and generics.
• The success of XHANCE will depend on its ability to capture market share from existing treatments and demonstrate superior clinical outcomes.

Legal Proceedings

• The company is party to legal proceedings that arose in connection with its definitive proxy statement on Schedule 14A filed with the SEC on April 15, 2025.
• The Merger Litigations generally allege that the Definitive Proxy Statement is materially incomplete and misleading by allegedly failing to disclose certain purportedly material information.
• Thirteen purported stockholders of OptiNose sent demand letters regarding the Definitive Proxy Statement.

Stakeholder Impact

• Shareholders will receive $9.00 in cash and one CVR per share upon completion of the merger.
• Employees face uncertainty regarding their future employment following the merger.
• Customers (patients and physicians) may experience changes in product availability and support services.
• Suppliers and creditors may be affected by the company's financial condition and the terms of the merger.

Next Steps

• Obtain stockholder approval for the merger agreement with Paratek Pharmaceuticals.
• Satisfy all closing conditions for the merger to be consummated.
• Enhance commercial performance to accelerate growth in net revenues.
• Seek out partnership and collaboration opportunities to expand the market for XHANCE.
• Request a modification or waiver of the covenants under the A&R Note Purchase Agreement, or refinance the debt, if required.
• Continue clinical development activities for XHANCE, including studies mandated under the Pediatric Research Equity Act.

Key Dates

Keywords

XHANCE, OptiNose, Paratek Pharmaceuticals, Merger, Chronic Rhinosinusitis, Net Product Revenues, Prescriptions, Financial Results, Debt Covenants, Going Concern